

[0712] Wei, H., Mundade, R., Lange, K. C., and Lu, T. (2014). Protein arginine methylation of non-histone proteins and its role in diseases. *Cell Cycle* 13, 32-41.

[0713] Weisberg, E., Ray, A., Barrett, R., Nelson, E., Christie, A. L., Porter, D., Straub, C., Zawel, L., Daley, J. F., Lazo-Kallanian, S., et al. (2010). Smac mimetics: implications for enhancement of targeted therapies in leukemia. *Leukemia* 24, 2100-2109.

[0714] Winter, G. E., Buckley, D. L., Pault, J., Roberts, J. M., Souza, A., Dhe-Paganon, S., and Bradner, J. E. (2015). Phthalimide conjugation as a strategy for in vivo target protein degradation. *Science* 348, 1376-1381.

[0715] Xie, T., Lim, S. M., Westover, K. D., Dodge, M. E., Ercan, D., Ficarro, S. B., Udayakumar, D., Gurbani, D., Tae, H. S., Riddle, S. M., et al. (2014). Pharmacological targeting of the pseudokinase Her3. *Nat Chem Biol* 10, 1006-1012.

[0716] Zengerle, M., Chan, K. H., and Ciulli, A. (2015). Selective Small Molecule Induced Degradation of the BET Bromodomain Protein BRD4. *ACS Chem Biol* 10, 1770-1777.

[0717] Raina, K., Lu, J., Qian, Y., Altieri, M., Gordon, D., Rossi, A. M., Wang, J., Chen, X., Dong, H., Siu, K., Winkler, J. D., Crew, A. P., Crews, C. M., and Coleman, K. G. (2016). PROTAC-induced BET protein degradation as a therapy for castration-resistant prostate cancer. *Proc. Natl. Acad. Sci. U.S.A* 113, 7124-7129.

1.-63. (canceled)

64. A bivalent compound comprising a protein arginine methyltransferase 5 (PRMT5) ligand conjugated to a degradation/disruption tag.

65. (canceled)

66. The bivalent compound of claim 64, wherein the PRMT5 ligand is EPZ015666, GSK591, EPZ015938, BLL-1, HLCL-61, LLY-283, or PF-06855800.

67. (canceled)

68. The bivalent compound of claim 64, wherein the degradation/disruption tag is pomalidomide, thalidomide, lenalidomide, VHL-1, adamantane, 1-((4,4,5,5,5-pentafluoropentyl)sulfinyl)nonane, nutlin-3a, RG7112, RG7338, AMG232, AA-115, bestatin, MV-1, or LCL161.

69. The bivalent compound of claim 64, wherein the degradation/disruption tag binds to a ubiquitin ligase or serves as a hydrophobic group that leads to PRMT5 protein misfolding.

70. The bivalent compound of claim 64, wherein the PRMT5 ligand is conjugated to the degradation/disruptor tag through a linker.


71. The bivalent compound of claim 64, wherein the bivalent compound has the form



wherein PI comprises an PRMT5 ligand and EL comprises a degradation/disruption tag.

72. The bivalent compound of claim 71, wherein PI comprises:

FORMULA 1



wherein A, B, C, and D are independently a bond, CR⁶, N, O, or S,

X and Z are independently CR⁷ or N,

Y is a bond, CR⁸, or N,


R¹, R², R³, R⁴, R⁵, R⁶, R⁷, and R⁸ are independently hydrogen, halogen, C₁-C₈ alkyl, C₁-C₈ alkoxy, or C₁-C₈ alkoxyalkyl,

m and n are independently 0-3, and

p is 0 or 1.

73. The bivalent compound of claim 71, wherein PI comprises:

FORMULA 2



wherein A, B, C, and D are independently a bond, CR⁶, N, O, or S,


Z is CR⁷ or N,

R¹, R², R³, R⁴, R⁵, R⁶, R⁷, and R⁸ are independently hydrogen, halogen, C₁-C₈ alkyl, C₁-C₈ alkoxy, or C₁-C₈ alkoxyalkyl, and

m, n, p, and q are independently 0-3.

74. The bivalent compound of claim 71, wherein PI comprises:

FORMULA 3



wherein A, B, C, and D are independently a bond, CR⁶, N, O, or S,

Y and Z are independently CR⁷ or N,

R¹, R², R³, R⁴, R⁵, R⁶, R⁷, and R⁸ are independently hydrogen, halogen, C₁-C₈ alkyl, C₁-C₈ alkoxy, or C₁-C₈ alkoxyalkyl, and

m, n, p, and q are independently 0-3.